Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Max S. Topp, Zachary Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, Anthony Stein, Janet Franklin, Qui Tran, Ze Cong, Andre C. Schuh

Blood (2018) 131 (26): 2906–2914.

https://doi.org/10.1182/blood-2017-09-804658

Published: 2018

Includes: Supplemental data

Journal Articles

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

Max S. Topp, MD, Zachary F. Zimmerman, MD PhD, Paul Cannell, MD, Herve Dombret, MD, Anthony S. Stein, MD, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong, PhD, Andre Schuh, MD FRCPC

Blood (2017) 130 (Supplement 1): 2571.

https://doi.org/10.1182/blood.V130.Suppl_1.2571.2571

Published: 2017

Journal Articles

A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)

Uwe Platzbecker, MD, Argiris Symeonidis, Esther N. Oliva, Jeroen S. Goede, Michel Delforge, Jiri Mayer, Borhane Slama, Sejal Badre, Eduard Gasal, Bhakti Mehta, Janet Franklin

Blood (2016) 128 (22): 2010.

https://doi.org/10.1182/blood.V128.22.2010.2010

Published: 2016

Journal Articles

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Max S Topp, MD, Zachary Zimmerman, MD PhD, Paul Cannell, MD, Hervé Dombret, MD PhD, Johan Maertens, MD PhD, Andre C. Schuh, MD FRCPC, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong

Blood (2016) 128 (22): 222.

https://doi.org/10.1182/blood.V128.22.222.222

Published: 2016

Journal Articles

Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study

Hagop Kantarjian, Pierre Fenaux, Mikkael A. Sekeres, MD, Jeffrey Szer, Uwe Platzbecker, MD, Andrea Kuendgen, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, MD, Nancy Carpenter, Bhakti Mehta, Janet Franklin, Aristoteles Giagounidis

Blood (2016) 128 (22): 2000.

https://doi.org/10.1182/blood.V128.22.2000.2000

Published: 2016

Journal Articles

Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Hagop Kantarjian, MD, Ghulam J. Mufti, MD PhD, Pierre Fenaux, MD PhD, Mikkael A. Sekeres, MD MS, Jeffrey Szer, MB BS FRACP, Uwe Platzbecker, MD, Andrea Kuendgen, MD, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, MD PhD, Janet Franklin, MD MPH, Aristoteles Giagounidis, MD

Blood (2015) 126 (23): 2863.

https://doi.org/10.1182/blood.V126.23.2863.2863

Published: 2015

Journal Articles

Safety and Efficacy of Long-Term Open-Label Dosing of Romiplostim in Thrombocytopenic Pediatric Patients (Pts) with Immune Thrombocytopenia (ITP)

James B. Bussel, MD, Michael D. Tarantino, Amy Geddis, Michael F. Guerrera, Alan K. Ikeda, Kun Nie, Janet Franklin, Melissa Eisen

Blood (2014) 124 (21): 4184.

https://doi.org/10.1182/blood.V124.21.4184.4184

Published: 2014

Journal Articles

Clinically Significant Mutations, Deletions and Translocations Involving ETV6 Identified by Whole Genome and Whole Exome Sequencing; Report From NCI/COG Target AML Initiative

Heather L. Helton, MD, Rhonda E. Ries, MA, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., Lisa R. Trevino, PhD, Jason Farrar, M.D., Jaime M. Guidry Auvil, Ph.D., Tanja M. Davidsen, PhD, Patee Gesuwan, Ph.D., Donna M. Muzny, Alan S. Gamis, MD, MPH, Janet Franklin, MD, MPH, David A. Wheeler, PhD, Malcolm A. Smith, MD, PhD, Daniela S. Gerhard, Ph.D., Robert J. Arceci, MD, PhD, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 125.

https://doi.org/10.1182/blood.V120.21.125.125

Published: 2012

Journal Articles

Expression of RUNX1 and RUNX1T1 Correlates with Cytogenetic Subgroups in Pediatric AML: A Report From the Children's Oncology Group

Matthew A. Kutny, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Janet Franklin, MD, MPH, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 1425.

https://doi.org/10.1182/blood.V120.21.1425.1425

Published: 2012

Journal Articles

Novel IL23R Splice Variant Is Associated with Worse Prognosis in Pediatric Patients with AML.

Derek L. Stirewalt, MD, Todd A. Alonzo, PhD, Era L. Pogosova-Agadjanyan, Robert B. Gerbing, M.A., Janet Franklin, MD, MPH, Susana C. Raimondi, Betsy A. Hirsch, PhD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 2546.

https://doi.org/10.1182/blood.V120.21.2546.2546

Published: 2012

Journal Articles

Novel IRF8 Splice Variants Are Validated As a New Prognostic Biomarker for Adverse Outcome in an Independent Population of Pediatric Patients with AML.

Derek L. Stirewalt, MD, Todd A. Alonzo, PhD, Era L. Pogosova-Agadjanyan, Robert B. Gerbing, M.A., Janet Franklin, MD, MPH, Hana Lee, Susana C. Raimondi, Betsy A. Hirsch, PhD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 2550.

https://doi.org/10.1182/blood.V120.21.2550.2550

Published: 2012

Journal Articles

Elevated BAALC Gene Expression Lacks Clinical Significance in Pediatric AML- A Report From the Children's Oncology Group.

Jessica A. Pollard, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., Phoenix A. Ho, MD, Susana C. Raimondi, Betsy A. Hirsch, PhD, Janet Franklin, MD, MPH, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 2553.

https://doi.org/10.1182/blood.V120.21.2553.2553

Published: 2012

Journal Articles

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group

Michael R. Loken, Todd A. Alonzo, Laura Pardo, Robert B. Gerbing, Susana C. Raimondi, Betsy A. Hirsch, Phoenix A. Ho, Janet Franklin, Todd M. Cooper, Alan S. Gamis, Soheil Meshinchi

Blood (2012) 120 (8): 1581–1588.

https://doi.org/10.1182/blood-2012-02-408336

Published: 2012

Journal Articles

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

Jessica A. Pollard, Todd A. Alonzo, Michael Loken, Robert B. Gerbing, Phoenix A. Ho, Irwin D. Bernstein, Susana C. Raimondi, Betsy Hirsch, Janet Franklin, Roland B. Walter, Alan Gamis, Soheil Meshinchi

Blood (2012) 119 (16): 3705–3711.

https://doi.org/10.1182/blood-2011-12-398370

Published: 2012

Journal Articles

TET2 Mutations Are Associated with Poor Outcome in Pediatric AML: A Report From the Children's Oncology Group

Matthew A. Kutny, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Daniel Geraghty, PhD, Alan S. Gamis, MD, MPH, Beverly Lange, MD, Nyla A. Heerema, PhD, Janet Franklin, MD, MPH, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Soheil Meshinchi, MD, PhD

Blood (2011) 118 (21): 569.

https://doi.org/10.1182/blood.V118.21.569.569

Published: 2011

Journal Articles

The Ratio of Alternate BIRC5 (Survivin) Splice Variants Correlates with Refractory Disease and Poor Outcome in Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group,

Andrew S. Moore, MBBS, FRACP, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., Beverly Lange, MD, Nyla A. Heerema, PhD, Janet Franklin, MD, MPH, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, Ph.D.

Blood (2011) 118 (21): 3555.

https://doi.org/10.1182/blood.V118.21.3555.3555

Published: 2011

Journal Articles

Clinical Significance of CD33 Non-Synonymous Single Nucleotide Polymorphisms (SNPs) in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozogamicin-Containing Chemotherapy,

Jatinder Lamba, PhD, Leslie J. Mortland, MD, Amit Mitra, Roland B. Walter, MD, PhD, Jessica A. Pollard, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., Betsy A. Hirsch, PhD, Susana C. Raimondi, PhD, Janet Franklin, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2011) 118 (21): 3489.

https://doi.org/10.1182/blood.V118.21.3489.3489

Published: 2011

Journal Articles

Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group

Todd A. Alonzo, PhD, Phoenix A. Ho, MD, Robert B. Gerbing, MA, Alan S. Gamis, MD, MPH, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Todd Cooper, DO, Janet Franklin, MD, MPH, Laura Pardo, Michael R. Loken, PhD, Soheil Meshinchi, MD, PhD

Blood (2010) 116 (21): 761.

https://doi.org/10.1182/blood.V116.21.761.761

Published: 2010

Journal Articles

The WT1 synonymous SNP rs16754 Is Associated with Higher mRNA Expression and Predicts Significantly Improved Outcome In Favorable-Risk Pediatric AML: a Report From the Children's Oncology Group

Phoenix A. Ho, MD, Julia Kuhn, BA, Robert B. Gerbing, MA, Jessica A. Pollard, MD, Rong Zeng, BS, Kristen L. Miller, BS, Nyla A. Heerema, Ph.D., Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Janet Franklin, MD, MPH, Beverly Lange, MD, Alan S. Gamis, MD, MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD

Blood (2010) 116 (21): 950.

https://doi.org/10.1182/blood.V116.21.950.950

Published: 2010

Journal Articles

Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group

Soheil Meshinchi, MD, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Phoenix A. Ho, MD, Alan S. Gamis, MD, MPH, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Todd Cooper, DO, Janet Franklin, MD, MPH, Laura Pardo, Michael R. Loken, PhD

Blood (2010) 116 (21): 1702.

https://doi.org/10.1182/blood.V116.21.1702.1702

Published: 2010

NARROW

Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study

Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Safety and Efficacy of Long-Term Open-Label Dosing of Romiplostim in Thrombocytopenic Pediatric Patients (Pts) with Immune Thrombocytopenia (ITP)

Clinically Significant Mutations, Deletions and Translocations Involving ETV6 Identified by Whole Genome and Whole Exome Sequencing; Report From NCI/COG Target AML Initiative

Expression of RUNX1 and RUNX1T1 Correlates with Cytogenetic Subgroups in Pediatric AML: A Report From the Children's Oncology Group

Novel IL23R Splice Variant Is Associated with Worse Prognosis in Pediatric Patients with AML.

Novel IRF8 Splice Variants Are Validated As a New Prognostic Biomarker for Adverse Outcome in an Independent Population of Pediatric Patients with AML.

Elevated BAALC Gene Expression Lacks Clinical Significance in Pediatric AML- A Report From the Children's Oncology Group.

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

TET2 Mutations Are Associated with Poor Outcome in Pediatric AML: A Report From the Children's Oncology Group

The Ratio of Alternate BIRC5 (Survivin) Splice Variants Correlates with Refractory Disease and Poor Outcome in Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group,

Clinical Significance of CD33 Non-Synonymous Single Nucleotide Polymorphisms (SNPs) in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozogamicin-Containing Chemotherapy,

Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group

The WT1 synonymous SNP rs16754 Is Associated with Higher mRNA Expression and Predicts Significantly Improved Outcome In Favorable-Risk Pediatric AML: a Report From the Children's Oncology Group

Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only